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Myofibroblasts play important roles in inflammation, fibrosis and tumorigenesis in
chronically inflamed liver. Liver myofibroblasts originate from hepatic stellate cells,
portal fibroblasts or mesothelial cells, and they are localized in and around fibrotic
septum and portal tracts. Liver myofibroblasts are the source of extracellular matrix
materials, including type I collagen and multiple fibrogenic growth factors, such as
transforming growth factor-β and vascular endothelial growth factor. Although a detailed
characterization of the function of individual myofibroblasts has not been conducted,
owing to the lack of appropriate cell markers, recent lineage-tracing technology has
revealed the limited contribution of myofibroblasts that are derived from portal fibroblasts
to various types of liver fibrosis, as compared with the contribution of hepatic stellate
cells. In addition, cytoglobin, which is the fourth globin in mammals and function as a
local gas sensor, provides a new perspective on the involvement of stellate cells in fibrosis
and carcinogenesis, possibly through its anti-oxidative properties and is a promising new
marker that discriminates between myofibroblasts derived from stellate cells and those
from portal fibroblasts.
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INTRODUCTION
Themyofibroblast was originally described by Gabbiani in the granulation tissue of healing wounds
as a cell type that had characteristics of fibroblasts and smooth muscle cells (Gabbiani et al., 1971).
In the liver, myofibroblasts were first identified in hepatic schistosomal fibrosis (Grimaud and
Borojevic, 1977); this was followed by the identification of contractile fibroblasts (myofibroblasts)
in chronic alcoholic cirrhosis (Rudolph et al., 1979).
Liver myofibroblasts are featured by the expression of α-smooth muscle actin (α-SMA), which
is encoded by ACTA2 gene located in 10q22-q24 in the human genome (Schmitt-Gräff et al., 1991).
The origin of liver myofibroblasts is complex: at least three cellular sources—hepatic stellate cells
(HSCs), portal fibroblasts (PFs), and mesothelial cells (MCs)—are considered to transdifferentiate
to liver myofibroblasts (Yin et al., 2013). The contribution of each type of myofibroblast to the
development or resolution of liver fibrosis varies depending on the etiology of liver disease.
Abbreviations: ABCRYS, α-B-crystallin; α-SMA, α-smooth muscle actin; BDNF, brain-derived nerve growth factor; Cygb,
cytoglobin; ET-1, endothelin-1; ECM, extracellular matrix material; GFAP, glial fibrillar acidic protein; HSC, hepatic stellate
cell; HIF, hypoxia inducible factor; LOX, lysyl oxidase; MMP, matrix metalloproteinase; MC mesothelial cell; NGF, neuronal
growth factor; NT, neurotrophin; NO, nitric oxide; PDGF, platelet-derived growth factor; PF, portal fibroblast; TIMP, tissue
inhibitor of matrix metalloproteinases; TGF-β, transforming growth factor β; TNF, tumor-necrosis factor; VEGF, vascular
endothelial growth factor.
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Conversely, cytoglobin (Cygb) belongs to the mammalian
globin family, which consists of myoglobin, hemoglobin,
neuroglobin, and androglobin (Burmester and Hankeln, 2014).
Cygb was accidentally discovered in rat HSCs during the
proteomics analysis of proteins that are expressed in HSCs. The
amino acid sequence and gas-binding ability of Cygb are similar
to those of myoglobin, thus suggesting that these two globins
have the same primary function in pathophysiology (Kawada
et al., 2001; Burmester et al., 2002; Trent and Hargrove, 2002).
However, recent studies have suggested that Cygb is involved in
the carcinogenesis of various organs, which is different from the
function of myoglobin, a gas-binding sensor that affects muscle
cell contraction (Shivapurkar et al., 2008; Shaw et al., 2009; Latina
et al., 2015).
In this review, we will discuss the role of Cygb, which is
uniquely expressed in HSCs in the liver, in the myofibroblastic
transformation of HSCs and carcinogenesis in the liver.
LIVER MYOFIBROBLASTS
In 2002, Cassiman et al. proposed the presence of at least
four different subpopulations of myofibroblasts in human liver.
Portal myofibroblasts and septal myofibroblasts are located
in the extended collagenous area around portal tracts and
in the internal region of fibrotic septa, respectively. These
myofibroblasts are strongly positive for α-SMA, and they
exhibit a variable positivity to glial fibrillar acidic protein
(GFAP), brain-derived nerve growth factor (BDNF) and α-
B-crystallin (ABCRYS). The third type of myofibroblasts is
interface myofibroblasts, which present at the edge between
fibrotic septa and the surrounding hepatic parenchyma, which
are positive for α-SMA, GFAP, and ABCRYS as well as BDNF,
neuronal cell adhesion molecule (N-CAM), neuronal growth
factor (NGF) and neurotrophin 4 (NT-4). The fourth type is
activated HSCs that are located in or around sinusoidal capillary
and within pseudo-lobules and express intensively α-SMA and
N-CAM and are positive for GFAP, NGF, BDNF, NT-3, and
synaptophysin as well as NT-4, ABCRYS, p75 and the NT
receptors tyrosine kinase A and B. Cassiman et al. proposed
that portal myofibroblasts, in addition to activated HSCs, may
originate from PFs (Cassiman et al., 2002). Recent cell-tracing
technology has clarified the origin of myofibroblasts in further
detail, as discussed below.
Hepatic Stellate Cells
HSCs reside in Disse’s space in the hepatic sinusoid, a space
between sinusoidal endothelial cells and hepatocytes (Wake,
1980). HSCs constitute approximately 10% of total liver cells
in the adult healthy liver. In healthy situation, quiescent HSCs
principally store vitamin A in droplets in their cytoplasm. It is
calculated that HSCs in the liver store 45–72% of vitamin A in
the body. Quiescent HSCs are positive for neural crest markers
like GFAP and NTs, nerve growth factor receptor (p75), and
desmin. Quiescent HSCs are the source of extracellular matrix
materials (ECMs) and the component of basement membrane-
like structure, such as laminin, proteoglycan, and type IV collagen
(Friedman, 2008; Yin et al., 2013; Pellicoro et al., 2014). HSCs
also function as liver-specific pericytes surrounding sinusoidal
endothelial cells, and thus their contractility is regulated by
the exposure to endothelin-1 (ET-1), angiotensin-II, and their
relaxation by nitric oxide (NO) control the diameter of sinusoids
and regulates the hepatic microcirculation (Kawada et al.,
1993).
Liver trauma caused by hepatitis virus B or C infection,
alcohol abuse, drug toxicity, autoimmunity, or steatohepatitis,
triggers the activation of HSCs and their transdifferentiation
from quiescent phenotype to myofibroblast-like one (Novo
et al., 2014). The myofibroblast-like HSCs contain less amount
of vitamin A droplets, express increased α–SMA and growth
factor receptors, possess augmented contractility, and generate
multiple ECMs, including type I and III collagens (Friedman,
2008; Yin et al., 2013; Pellicoro et al., 2014). This activation
process of HSCs is initiated by paracrine stimulation by
neighboring and activated sinusoidal endothelial cells, Kupffer
cells (liver macrophages), hepatocytes and cholangiocytes, as
well as platelets. When activated, HSCs synthesize transforming
growth factor β (TGF-β), which stimulates HSCs themselves
as an autocrine loop. Hepatic sinusoidal endothelial cells take
part in the activation of TGF-β from its latency-associated
peptide-binding form by its proteolytic cleavage (Schuppan
and Kim, 2013). Cholangiocytes and platelets are also an
important origin of growth factors, including platelet-derived
growth factor (PDGF), TGF-β, and epidermal growth factor.
Activation of HSCs is additionally initiated by damaged
hepatocytes; they secrete fibrogenic lipid peroxides, and their
apoptosis mediated by Fas and tumor-necrosis factor (TNF)-
related apoptosis-inducing ligand initiates the activation of
HSCs via damage-associated molecular pattern molecules
including high-mobility group box 1, RNA and DNA, S100
molecules, and purine metabolites. In culture system, it was also
demonstrated that apoptotic fragments derived from damaged
hepatocytes stimulate HSC activation, and that fibrogenic
activity of myofibroblasts are augmented by the phagocytosis
of apoptotic hepatocytes due to NADPH oxidase 2 and the
janus kinase/signal transducer and activator of transcription
and phosphoinositide 3-kinase/Akt pathways (Wree et al.,
2014). Activated HSCs also produce an increased amount of
matrix metalloproteinases (MMPs), especially MMP13, and
their inhibitors, tissue inhibitor of matrix metalloproteinases
(TIMPs).
Transcription factors including activated protein-1, Jun
D, Sp1, Kruppel-like factor 6, and nuclear factor kappa B,
whose functions are strictly regulated by intracellular signaling
molecules, such as Smad, Ras, Raf-1, and mitogen-activated
protein kinase, control the activation of HSC, leading to
the transcriptional upregulation of latent TGF-β (Mann and
Smart, 2002; Lopez-Sanchez et al., 2014). Epigenetic regulation,
specifically DNA methylation and histone modification, is also
important in the regulation of the activation of HSCs. For
example, the abnormal DNA methylation of phosphatase and
tension homolog (PTEN) and MeCP2 has been identified in
activated HSCs (Lee et al., 2015). Among epigenetic signals,
microRNAs also participate in the activation of HSCs. The
microRNAs that have been implicated in HSC activation
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include miR-199a,b, miR-221, miR-27, miR-21, miR-125, miR-
195, miR-214, and miR-221/222 as profibrotic miRNAs, and
miR-29, miR-15b, miR-200, miR-16, miR-133b, and miR-122
as anti-fibrotic miRNAs. Among these miRNAs, miR-29 has
been the most intensively analyzed for its ability to suppress
collagen 1A1 production in HSCs (Sekiya et al., 2011; Ogawa
et al., 2012). In addittion, the augmented production of TIMPs
impedes ECM degradation and triggers ECM accumulation in
the damaged liver (Perugorria et al., 2013). It should be noted
that leptin and other adipocytokines are involved in the process
of HSC activation (Choi et al., 2010) and that activated HSCs are
additionally characterized by augmented expression of receptors
for PDGF, TGF-β, vascular endothelial growth factor (VEGF),
angiotensin-II, and ET-1 (Novo et al., 2012). Through study of
reporter Collagen α1(I)-GFP (Col-GFP) mice, GFP+Vitamin-
A+Desmin+ activated HSCs have been shown to comprise more
than 92% of myofibroblasts in the fibrotic liver induced by CCl4
intoxication (Scholten et al., 2010).
Hepatocellular carcinoma (HCC) is a consequence of chronic
liver disease with many etiologies, and it develops after repetitive
hepatocyte death and the development of fibrosis. In fact, it is
thought that 80% of HCC develop in fibrotic and cirrhotic liver.
Thus, fibrosis consisting of HSC-derived myofibroblasts may be
involved in cancer development. Because activated HSCs are
the source for growth factors and ECMs as mentioned above,
they may contribute to the development of a microenvironment
that is suitable for cancer growth. In fact, Coulouarn et al.
demonstrated the importance of HSC-hepatocyte interaction due
to the production of VEGFA and MMP-9 (Coulouarn et al.,
2012). Very recently, Yoshimoto et al. elucidated that senescent
HSCs activated by a bile acid derived from intestinal microbiota
shows a senescent-associated secretary phenotype, in which a
panel of cytokines, such as IL-1, IL-6, and GROα, are synthesized.
This phenomenon is suggested in the central scenario for the
development of liver cancer in obesity (Yoshimoto et al., 2013).
Portal Fibroblasts
PFs are the resident fibroblasts around the portal tract existing
in the mesenchyme surrounding the bile ducts. PFs were first
described more than 50 years ago in rat liver. It is considered that
PFs in addition to HSC-derived myofibroblasts produce ECMs
particularly in case of biliary fibrosis (Wells, 2014).Although it is
considered that the septum tranversum-derived mesothelial cells
are origin of PFs and HSCs, the definition of the roles of PFs
in normal and injured liver has been unsatisfactory confirmed
due to the lack of reliable markers to distinguish PFs from HSCs.
PFs are generally positive for gremlin, Thy-1, fibulin 2, elastin,
interleukin 6 (IL-6), cofilin, and the ectonucleotidase NTPDase
2. Lemoinne et al. demonstrated that COL15A1-positive portal
and periportal cells give rise to portal myofibroblasts and
release VEGFA-laden microparticles, thus promoting endothelial
tubulogenesis (Lemoinne et al., 2015). Unlike HSCs, PFs lack
desmin, cytoglobin, β2-macroglobulin, Hand2, GFAP, p75NGFr,
and Vitamin A. Using a mouse model carrying a bacterial
artificial chromosome with a Cre reporter derived from the
lecithin-retinol acyltransferase, Mederacke et al. recently showed
that HSCs are the source of 82–96% of myofibroblasts in
seven models of fibrosis in mice, although they could not
eliminate the possibility that PFs are required for biliary fibrosis.
Particularly, bridging fibrosis occurs from the portal vein area
to the central vein area where PFs and desmin–negative cells
are localized (Mederacke et al., 2013). Iwaisako et al. showed
the important role of myofibroblasts derived from PFs during
the initial stages of bile-duct ligation-induced liver fibrosis by
contributing more than 70% of myofibroblasts, although HSC-
derived myofibroblasts become dominant at the last phase
(Iwaisako et al., 2014). In their study, Iwaisako et al. also
identified mesothelin as a useful marker to distinguish PF-
myofibroblasts from HSC-myofibroblasts.
PFs can be differentiated from HSCs-myofibroblasts by their
production of elastin. As mentioned before, PFs were originally
defined by their fibulin 2 expression (Knittel et al., 1999).
Fibulin 2 is a linker protein that occupies the interface between
microfibrils and their elastin core. Fibulin 2 mediates the
progression of fibrosis by sequestering latent TGF-β binding
proteins from TGF-β. In addition, PFs produce lysyl oxidase
(LOX) and the related protein LOX-like 1, which cross-links
elastin. Taken together, the function of PFs should be estimated
regarding to the metabolism of elastin since elastin fibers are
able to provide the bile ducts and the portal vasculature with
mechanical stability (Perepelyuk et al., 2013).
The interaction of PFs with cholangiocytes is another
important issue. Tanimizu et al. described that neurotrophin
receptor p75-positive progenitors of PFs and cholangiocytes
express laminin α1 and α5 subunits, respectively, which interact
with the β1 integrin subunit to maintain the polarity and lumen
of the bile ducts (Tanimizu et al., 2012). On the other hand,
Jhandier et al. reported that PF-derived myofibroblasts do not
express ectonucleotidase NTPDase2, which is equivalent to ecto-
ATPase or CD39L1 and metabolizes extracellular nucleotides.
This fact may explain how cholangiocyte proliferation is initiated
by P2Y receptor activation in chronic cholangiopathies (Jhandier
et al., 2005).
Mesodermal Mesenchymal Cells
Although myofibroblasts are able to be derived from epithelial
cells like hepatocytes and cholangiocytes, during the epithelial-
to-mesenchymal transition, recent genetic cell lineage tracing
has clearly revealed that mesenchymal cells including HSCs,
PFs, and vascular smooth muscle cells are derived from MCs
in the mouse embryonic liver. In addition, in adult Wt1CreERT2;
R26T/Gf mice after the induction of fibrosis by CCl4 or bile duct
ligation, MCs that are positive for glycoprotein M6a, podoplanin
and CD200 acquire mesenchymal characteristics—expression of
collagen 1α1 and vimentin—but the epithelial cell markers are
decreased. This phenomenon of the conversion of liver MCs
to mesenchymal cells is called the mesothelial-mesenchymal
transition. The canonical TGF-β pathway plays a central role in
MMT via SMAD3 (Li et al., 2013; Yin et al., 2013; Lua et al., 2014).
CYTOGLOBIN
Cygb belongs to the mammalian globin family including
myoglobin in muscle cells, hemoglobin in red blood cells,
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neuroglobin in the nervous system, and androglobin in testis.
Cygb, originally named stellate cell activation-associated protein
by our group and histoglobin by Trent and Hagrove, was
discovered in 2001 from cultured rat HSCs by proteomics
analysis, namely the separation of proteins expressed in HSCs
by 2D SDS-PAGE, followed by the identification of individual
proteins by time of flight mass spectrometry. The molecular
weight of Cygb is 21,496 Da, and it is composed of 190 amino
acids (Kawada et al., 2001; Trent and Hargrove, 2002; Burmester
and Hankeln, 2014).
Cygb is uniquely expressed in HSCs, but not in hepatocytes,
endothelial cells, or Kupffer cells, in the liver (Figure 1). Cygb
is also expressed in extrahepatic organs, including the pancreas,
spleen, kidney, digestive tract, and heart. Cygb-positive cells
usually localize proximally to capillaries, and they are considered
to be pericytes that store vitamin A, produce collagen and
closely correlate with vascular endothelium (Nakatani et al.,
2004). In addition, Cygb is expressed in chondrocytes, osteoblasts
and osteocytes (Schmidt et al., 2004). Furthermore, a recent
report has indicated that Cygb is expressed in melanocytes
and several types of melanoma, and it is involved in the
melanocyte-to-melanoma transition through hyper-methylation
in the promoter region of the CYGB gene (Fujita et al.,
2014).
The 3D structure of Cygb is almost identical to that of
myoglobin, and it has a three-over-three α-helical sandwich
structure consisting of eight helices, whereas Cygb is a bis-
histidyl hexa-coordinate globin similar to neuroglobin and
different from myoglobin and hemoglobin, which are penta-
coordinate globins. However, Cygb can bind gas molecules
including oxygen, nitric oxide, and carbonmonoxide with kinetic
properties similar to those of myoglobin. Thus, Cygb is thought
to function as a local gas-sensor (Makino et al., 2006, 2011). A
recent report has indicated the role of Cygb as a nitric oxide
dioxygenase [Cygb(Fe2+)→ O2 → Cygb(Fe2+−O2)→ NO→
FIGURE 1 | Cytoglobin expression in intact human liver. Cytoglobin
(arrows) is localized along hepatic sinusoid, namely these cells are identical to
hepatic stellate cells, but not hepatocytes. Intact human liver tissue was
obtained at Osaka City University Hospital under the patient’s consent
(Motoyama et al., 2014). Written informed consent was obtained from the
patient. NK contributed to the evaluation of diagnosis of human liver
histopathology.
Cygb(Fe3+) + NO−3 ] resulting in the regulation of the local
concentration of nitric oxide and hence vascular tonus (Liu et al.,
2012).
Cygb gene expression is regulated by hypoxia inducible factor-
1 (HIF-1), which binds to the hypoxia response element of the
Cygb gene promoter. In fact, exposure of HeLa cells to 1% O2
upregulates Cygb mRNA expression 1.7-fold (3 h) and 1.6-fold
(6 h) in culture. HIF-1 and erythropoietin have 2 (-141 and -
448) and 1 (-144) binding site, respectively, within the 5′-UTR
lesion of the Cygb gene; these sites are important for Cygb
gene transcription under hypoxia (Guo et al., 2007). The other
transcription factors involved in Cygb gene expression include c-
Ets-1, Sp1, nuclear factor of activated T cell and activator protein
(Guo et al., 2006). In case of the liver, Cygb is induced during
hypoxia (24 and 48 h at 7% O2) and reoxygenetion in mice
(Fordel et al., 2007). Man et al. demonstrated that more than
3.5-fold upregulation of CygbmRNA expression and the increase
in the number of Cygb-expressing cells after the administration
of CCl4 in mice (Man et al., 2008). Gninsky et al. reported
the induction of Cygb in thioacetamide-intoxicated liver fibrosis
model in rats, which was clearly suppressed by the treatment
with halofuginone, an inhibitor of TGF-β-dependent Smad3
phosphorylation (Gnainsky et al., 2007). In culture studies, Cui
et al. demonstrated the induction of Cygb in primary-cultured
rat HSCs by arundic acid, an inhibitor of S100b synthesis in
astrocytes (Cui et al., 2012). Stone et al. recently clarified the
regulation of Cygb expression in HTC-T6 cells in culture; Cygb
expression is upregulated by laminin via integrin α1β4 signaling
while it is downregulated by type I collagen by phosphorylation
of focal-adhesion kinase via integrin α2β1 signaling (Stone et al.,
2015).
Although Cygb’s function as a fas-binding molecule is well-
established, its pathophysiological role has not been fully
elucidated. Cygb protects SH-SY5Y neuroblastoma cells from
apoptosis under exposure to 300µM H2O2 (Fordel et al., 2006).
Li et al. demonstrated that siCygb treatment facilitates N2a
neuronal cell death under exposure to 500µM H2O2 for 4 h (Li
et al., 2007). These and other studies have revealed that Cygb is a
possible cytoprotector against oxidative stress.
Recently, the role of Cygb in human carcinogenesis in various
organs has been paid special attention. The downregulation
of Cygb gene expression has been demonstrated in human
esophageal cancer, head and neck cancer, lung cancer, ovarian
cancer and prostatic cancer via the hyper-methylation of the
promoter lesion of the Cygb gene (Shivapurkar et al., 2008; Shaw
et al., 2009; Latina et al., 2015). In detail, Oleksiewicz et al.
showed (1) marked down-regulation of Cygb protein in human
lung cancer cell line compared to normal human epithelial cell
lines and possible involvement of promoter methylation and (2)
significantly reduced Cygb mRNA expression in non-small cell
lung cancer tissues compared with normal lung tissue (Mann-
Whitney test, P = 2.3 × 10−7), suggesting the possible tumor
suppressor function of Cygb (Oleksiewicz et al., 2013). Based
on these reports, Hubers et al. studied Cygb gene methylation
in spontaneous sputum in order to utilize it for lung cancer
diagnosis. As a result, they reported the sensitivity of Cygb for
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the diagnosis of lung cancer was 22% (Hubers et al., 2014). Except
for the lung cancer, Wojnarowicz et al. demonstrated that Cygb
gene expression was lowered in the majority of tumors with
low malignant potential and cancer compared to benign tumors
and normal ovarian surface epithelial cell samples (Wojnarowicz
et al., 2012). Chen et al. also clarified the involvement of Cygb
in ovarian cancer development at human tissue level and in cell
culture models (Chen et al., 2014). Similar observations were
additionally reported in human atrophy and adenocarcinoma of
the prostate, suggesting that prostaticmalignancy is accompanied
with low level of Cygb, which play a role in protecting from
oxidative damage (Mogal et al., 2012).
Using Cygb-knockout mice that were generated in our
laboratory, we studied the role of Cygb in liver cancer
development. First, mice were treated with 0.05 ppm
diethylnitrosamine, an established carcinogen to the liver,
for 36 weeks, thus resulting in the occurrence of liver tumors
in 57.1% of the knockout mice compared with 0% of the
wild-type mice. In this model, background liver tissues showed a
marked development of liver fibrosis, augmented inflammatory
reactions and overproduction of peroxynitrite (ONOO−)
in knockout mice (Thuy le et al., 2011). Second, mice were
given a choline-deficient L-amino acid-defined diet for 32
weeks to induce steatohepatitis. Unexpectedly, 100% of Cygb
knockout mice developed multiple liver tumors compared
with 0% of the wild type mice. Again, background liver tissues
showed marked development of liver fibrosis and augmented
inflammatory reactions, which were accompanied by DNA
double strand breaks (γH2AX expression) in hepatocytes. These
results show the protective role of Cygb against oxidative stress
and liver fibrosis development under chronic inflammation,
suggesting Cygb’s role in tissue carcinogenesis (Thuy le et al.,
2015). In accordance with these observations, previous two
reports demonstrated the anti-fibrotic function of Cygb.
Xu et al. reported that Cygb overexpression in the liver by
recombinant adeno-associated virus-2 encoding full-length
rat Cygb suppressed liver injury and fibrosis induced by CCl4
adminstration or bile-duct ligation in rats (Xu et al., 2006)
and, furthermore, He at al. showed that administration of
recombinant Cygb (10mg/Kg) attenuates liver fibrosis in
thioacetamide-induced liver fibrosis in rats (He et al., 2011),
suggesting the hepato-protective role of Cygb.
CYTOGLOBIN AS A MARKER OF HEPATIC
STELLATE CELL-DERIVED
MYOFIBROBLASTS
As mentioned above, Cygb was initially discovered from rat
HSCs in primary culture (Kawada et al., 2001). Cygb is
expressed in mouse and human HSCs (Figure 1). Thus, whether
Cygb can be utilized as a specific marker to distinguish
myofibroblasts derived from HSCs from those derived from
PFs is an interesting issue. Schmidt et al. first provided a
detailed description of Cygb-expressing cells in vivo in mice,
and they demonstrated that, in the liver, Cygb is expressed
in HSCs and fibroblasts that surround the portal vein, but
not in hepatocytes (Schmidt et al., 2004). However, in this
study, fibroblasts around the portal vein were insufficiently
characterized. Using fibulin 2 as a PF marker, Tateaki et al.
demonstrated that there are several types of fibroblastic cells
in the liver, namely fibulin 2+/Cygb+, fibulin 2+/Cygb−,
fibulin 2−/Cygb+, fibulin 2−/Cygb−, and they concluded that
fibulin 2+/Cygb+ and fibulin 2−/Cygb+ are identical to portal
myofibroblasts and activated HSCs, respectively. A limitation
of this study is that the identification of individual cell types
was performed only by immunofluorescence staining (Tateaki
et al., 2004). Ogawa et al. isolated the mouse liver non-
parenchymal cell fraction by the Nycodenz density gradient
method and further separated the cells in the fraction on the
basis of vitamin A autofluorescence with FACS. UV+ cells had
minimum growth potential, expressed desmin and Cygb, but
not αSMA and fibulin 2 at 1 day in culture, and later became
positive for desmin, Cygb, and αSMA at 7 day in culture.
Hence, UV+ cells (vitamin A-storing cells) are identical to HSCs.
Conversely, UV− cells showed high proliferation activity and
expressed αSMA, fibulin 2, and Gremlin, but not desmin and
Cygb, thus indicating that UV− cells are derived from portal
fibroblasts (Ogawa et al., 2007). Bosselut at al. demonstrated
that isolated rat portal myofibroblasts do not express Cygb,
and thus are different from rat HSCs, as determined by 2-D
MS/MS (Bosselut et al., 2010). Recent study by Fausther et al.
described that rat portal fibroblasts and portal myofibroblast cell
lines, RGF and RGF-N2, express Cygb at least in mRNA level
in culture model (Fausther et al., 2015). In contrast, Motoyama
et al. demonstrated that in human liver damaged by chronic
FIGURE 2 | Cytoglobin expression in fibrotic human liver. Cytoglobin (arrows) is localized along hepatic sinusoid, while α-SMA and Thy-1, myofibroblast markers,
were strongly positive at fibrotic septum. Human liver tissue with fibrosis caused by chronic hepatitis C was obtained at Osaka City University Hospital under the
patient’s consent (Motoyama et al., 2014). Written informed consent was obtained from the patients. NK contributed to the evaluation of diagnosis of human liver
histopathology.
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hepatitis C, Cygb- and cellular retinol-binding protein-positive
cells localize along hepatic sinusoids in liver parenchyma and
at the margin of fibrotic septum, and they are not identical to
αSMA, fibulin 2, and Thy-1-positive myofibroblasts (Motoyama
et al., 2014; Figure 2). In summary, in mouse, rat, and human
liver, Cygb is expressed in quiescent HSCs, and its expression
level increases in activated HSCs that also express αSMA. In
contrast, myofibroblasts derived from PFs are positive for fibulin
2 and αSMA, and they are negative for Cygb in human, while in
rodent Cygb expression in PF-derived myofibroblasts needs to be
characterized further by, for example, using genetic cell-labeling
technology.
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